Method and composition for treatment of insulin resistance syndromes
US5422125A · kind A · utility
24Cited by
5References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 12, 1994 |
| Grant date | Jun 6, 1995 |
| Priority date | — |
| Expiry date | Oct 12, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating human or animal patients suffering from insulin resistance syndromes, particularly diabetes mellitus, by administering an effective amount of the compound magnesium vanadate. Daily dosage ranges are preferably from about 2 to about 60 mg per kg of patient body weight. Pharmaceutical compositions for use in the method of treatment include magnesium vanadate and at least one pharmaceutically acceptable inert ingredient, and may be oral, parenteral, transdermal or transmucosal dosage forms containing from about 50 to about 1000 mg of magnesium vanadate per unit.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.